Document Detail


Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
MedLine Citation:
PMID:  1619019     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted of 22 patients who received Parlodel LAR before transsphenoidal adenomectomy; group II was composed of 7 patients with earlier neurosurgery and of 2 patients from group I not cured by transsphenoidal adenomectomy. Duration of therapy varied from 1-12 months, and a total of 104 injections was given. At nadir day, serum PRL levels were situated between less than 1% and 43% of pretreatment values. At day 28 after the first injection, serum PRL levels varied between less than 1% to 139% of initial values. No difference could be detected between the two groups regarding the percent of PRL inhibition. Long-term treatment with Parlodel-LAR resulted in a sustained inhibition of PRL secretion, except for 1 case. Resumption of menstrual cycles occurred in 4 out of 15 women and correction of hypogonadism in 4 out of 14 men. Amelioration of disturbed visual fields was recorded in 3 out of 8 patients. Diminution of the adenoma volume was radiologically documented in 14 out of 22 cases. Only few and mild side effects were recorded. One patient with partial adrenal deficiency suffered from a syncope, but this was prevented by hydrocortisone supplementation during the subsequent Parlodel-LAR administration. In conclusion, Parlodel-LAR proved effective in the treatment of macroprolactinomas, achieving rapid inhibition of PRL secretion, and in some patients amelioration of hypopituitarism, reduction in tumor size, and improvement in visual fields, and caused no serious side effects. It is a valuable preparation to surgery and can also be used in long-term medical therapy.
Authors:
A Beckers; P Petrossians; R Abs; P Flandroy; T Stadnik; M de Longueville; I Lancranjan; A Stevenaert
Related Documents :
11124859 - Markers of tumor invasion are major predictive factors for the long-term outcome of cor...
1900379 - Pituitary function in thalassemic patients and the effect of chelation therapy.
14733699 - Long-term results of transperitoneal laparoscopic fenestration in the treatment of simp...
15497659 - Lessons from 6 years of gh receptor antagonist therapy for acromegaly.
9329359 - Effect of octreotide pretreatment on surgical outcome in acromegaly.
12532689 - Effect of the dose of oral hydrocortisone on growth rate during long-term treatment of ...
15729199 - Endoscopic therapy for gastroesophageal reflux disease: a systematic review.
21507029 - The efficacy of exclusive nutritional therapy in paediatric crohn's disease, comparing ...
1498319 - A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  75     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1992 Jul 
Date Detail:
Created Date:  1992-07-31     Completed Date:  1992-07-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  275-80     Citation Subset:  AIM; IM    
Affiliation:
Department of Endocrinology, University of Liège, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Bromocriptine / administration & dosage,  adverse effects,  therapeutic use*
Delayed-Action Preparations
Female
Humans
Injections, Intramuscular
Male
Middle Aged
Nausea / chemically induced
Pituitary Gland / physiology
Pituitary Neoplasms / drug therapy*
Prolactin / blood,  secretion
Prolactinoma / drug therapy*
Chemical
Reg. No./Substance:
0/Delayed-Action Preparations; 25614-03-3/Bromocriptine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Persistence of impaired insulin secretion in infant rhesus monkeys that had been hyperinsulinemic in...
Next Document:  Growth hormone-releasing hormone-like messenger ribonucleic acid and immunoreactive peptide are pres...